Newstral
Article
bizjournals.com on 2015-10-16 14:25
FDA rejects AstraZeneca's experimental diabetes therapy
Related news
- FDA rejects NRx's breakthrough designation bid for experimental Covid-19 therapy; stock price fallsbizjournals.com
- FDA rejects AstraZeneca's new drug application for blood disorder treatmentbizjournals.com
- FDA grants emergency approval to experimental COVID-19 antibody therapynewatlas.com
- FDA rejects Sunovion's experimental drug to treat Parkinson'sbizjournals.com
- FDA approves AstraZeneca's gout medicinebizjournals.com
- IFDA Rejects MDMA Therapy Application, Calls for More Researchinvezz.com
- BBioMarin Slumps After FDA Rejects Its Hemophilia Gene Therapybarrons.com
- FDA Rejects Oral Treatment for Type 1 Diabeteswsj.com
- FDA approves expanded access to Wilmington company's experimental Covid-19 therapybizjournals.com
- Bucks County biotech gets FDA approval to begin mid-stage testing of experimental Covid-19 therapybizjournals.com
- FDA grants two key designations to Passage Bio's experimental Krabbe disease therapybizjournals.com
- FDA authorizes AstraZeneca's COVID-19 antibody cocktailisraelnationalnews.com
- Intarcia raises $215 million as it gets ready to seek FDA OK for experimental diabetes treatmentbizjournals.com
- MAstraZeneca's Farxiga gets U.S. FDA approvalmarketwatch.com
- FDA rejects NRx Pharmaceuticals' emergency use request for its experimental Covid-19 treatmentbizjournals.com
- RAfter FDA rejects MDMA therapy for PTSD, Texas veteran continues to advocaterssfeeds.kvue.com
- IAgenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapyinvezz.com
- FDA approves first generic version of AstraZeneca's Nexiumbizjournals.com
- FDA rejects insulin pump from diabetes drug-delivery developer with key East Bay sitebizjournals.com